Medical Writing. Sandoz, a generic company that belongs to the Novartis Group, has announced that the European Medicines Agency (EMA) has accepted the application to submit the registration of the biosimilar of Amgen's Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor. (G-CSF), requesting approval for the same indication as the reference product.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
